The increasing importance of treatment of lower urinary tract symptoms (LUTS), while avoiding side effects and maintaining sexual function, has allowed for the development of minimally invasive surgical therapies (MISTs). Recently, the European Association of Urology guidelines reported a paradigm shift from the management of benign prostatic hyperplasia (BPH) to the management of nonneurogenic male LUTS. The aim of the present review was to evaluate the efficacy and safety of the most commonly used MISTs: ablative techniques such as aquablation, prostatic artery embolization, water vapor energy, and transperineal prostate laser ablation, and nonablative techniques such as prostatic urethral lift and temporarily implanted nitinol device (iTIND). MISTs are becoming a new promise, even if clinical trials with longer follow-up are still lacking. Most of them are still under investigation and, to date, only a few options have been given as a recommendation for use. They cannot be considered as standard of care and are not suitable for all patients. Advantages and disadvantages should be underlined, without forgetting our objective: treatment of LUTS and re-treatment avoidance.
Asian journal of andrology. 2023 Oct 31 [Epub ahead of print]
Gian Maria Busetto, Andrea Checchia, Marco Recchia, Edoardo Tocci, Ugo G Falagario, Gennaro Annunziata, Pasquale Annese, Nicola d'Altilia, Vito Mancini, Matteo Ferro, Felice Crocetto, Octavian Sabin Tataru, Luca Di Gianfrancesco, Angelo Porreca, Francesco Del Giudice, Ettore De Berardinis, Carlo Bettocchi, Luigi Cormio, Giuseppe Carrieri
University of Foggia, Foggia 71122, Italy., Urology Unit, "G. Tatarella" Hospital, Cerignola 71042, Italy., Department of Urology and Renal Transplantation, Policlinico of Foggia, Foggia 71122, Italy., Urology Unit, European Institute of Oncology (IEO) IRCCS, Milan 20141, Italy., University of Naples Federico II, Naples 80126, Italy., G. E. Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures 540142, Romania., Department of Oncological Urology, Veneto Institute of Oncology (IOV) IRCCS, Padua 35128, Italy., Department of Maternal-Infant and Urological Sciences, Sapienza Rome University, Roma 00161, Italy.